William Fearon, MD, Professor of Medicine and Director of Interventional Cardiology at Stanford University School of Medicine shares recent results from the FAME3 clinical trial. Dr. Fearon says previous trials, such as FAME1 showed a significant reduction in major cardiac events when comparing fractional flow reserve (FFR)-guided percutaneous coronary invention (PCI) to angiography-guided PCI, which was the standard of care at the time. The FAME3 trial compared FFR-guided PCI using current generation drug-eluting stents to coronary artery bypass surgery; however, the study concluded that FFR-guided PCI did not meet noninferiority standards.